In a SARS-CoV-2 challenge model, a single dose of the vaccine delivered sterilising immunity in the lungs of mice, while non-vaccinated mice went on to develop dense lung infection and...
The UK is leading the way with implementing human challenge trials as a way to...
India’s homegrown Covid-19 vaccine Covaxin was approved for emergency use back in January without any Phase III data. That data...
With supply-chain and shortage issues affecting the global rollout of Covid-19 vaccines, especially for the second dose, researchers are exploring...
The National Institutes of Health (NIH) has commenced subject enrolment in a Phase II/III ACTIV-2 trial of a new fully...
Top ten countries by Covid-19 vaccine doses administered to date (numbers in millions)
| Country | Millions of doses |
|---|---|
| China | 324.3 |
| United States | 259.7 |
| India | 168.3 |
| United Kingdom | 53 |
| Brazil | 46.9 |
| Germany | 34.4 |
| France | 25.4 |
| Turkey | 24.9 |
| Italy | 24 |
| Indonesia | 22 |
Ampio Pharmaceuticals has secured Investigational Review Board (IRB) approval for its Phase I trial against long-haul Covid-19. Named AP-018, the…
Telix Pharmaceuticals has begun a Phase III ProstACT clinical trial of its therapy candidate, TLX591 (177Lu-DOTA-rosopatamab), in advanced metastatic castrate-resistant…
The deal values Science 37 at an enterprise value of about $1.05bn. As per the merger agreement, the combined company,…
A human monoclonal antibody (mAb), Imfinzi attaches to programmed death-ligand 1 (PD-L1) while Tremelimumab, also a human mAb, hinders cytotoxic T-lymphocyte-associated protein 4’s (CTLA-4)…
Virtual reality has shown the potential to help patients deal with pain and anxiety during difficult procedures and clinical trials. Clinical Trials Arena speaks to...
THREAD, a tech-focused service provider that enables decentralised clinical trials, has recently penned a partnership with CureClick, a community-powered platform that harnesses social media influencers...
Akili Interactive has published data from its STARS-Adjunct trial supporting the efficacy of EndeavorRx, its attention-deficit hyperactivity disorder (ADHD) video game therapy for kids, in...
In a bid to put patient involvement at the heart of drug development and clinical trials, the Medicines and Healthcare products Regulatory Agency (MHRA) has...
The move towards decentralised clinical trials has been accelerated by Covid-19, and the tech that underpins remote trials is evolving at a matching pace. Clinical...
The Covid-19 pandemic has transformed clinical development. Rather than taking ten years to bring a drug to market, vaccine manufacturers showed a drug can be...
The COVID-19 pandemic has led to a surge in the use of remote patient monitoring (RPM) tools to monitor patients outside the standard healthcare settings.
The COVID-19 pandemic triggered unexpected challenges in the business environment prompting pharmaceutical companies to accelerate the adoption of digital transformation strategies.
© Copyright Verdict Media Limited 2021
Expert Commentary & Analysis
View MoreOrphazyme’s arimoclomol fails to show efficacy in a specific ALS population
On 7 May, Orphazyme, a Denmark-based late-stage biopharmaceutical company pioneering heat shock protein therapies for the treatment of rare diseases, announced that the ORARIALS-01 pivotal trial of arimoclomol in amyotrophic…
Angion’s ANG-3777 prior data, multitargeted MOA well-placed to tackle delayed graft function but faces uphill task in complex patient population
Angion Biomedica’s bid to treat delayed graft function (DGF) following kidney transplantation is strong with clinical signals and mechanistic potential. However, patient heterogeneity makes predicting clinical success a challenge, experts…
Vertex monopoly of the cystic fibrosis space signalled by another label expansion
On 28 April, the European Commission (EC) approved the label expansion for Vertex Pharmaceuticals' Kaftrio (ivacaftor/tezacaftor/elexacaftor + ivacaftor) for the treatment of cystic fibrosis (CF) in all patients aged 12…
LoA Update: Amgen’s Nplate in aplastic anemia soars 11 points in FDA likelihood of approval after posting strong trial results
The FDA Likelihood of Approval (LoA) for Amgen’s Nplate (romiplostim) in aplastic anaemia jumped 11 points as of 22 April, according to GlobalData’s LoA analysis. The update comes after Amgen posted…